Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033

Role of proinflammatory cytokines in the pathophysiology of osteoarthritis

Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.196 · Cited by 2,778

Graves' Ophthalmopathy

Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552

Toxicities of chimeric antigen receptor T cells: recognition and management

Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797

Mechanisms and therapeutic implications of cellular senescence in osteoarthritis

Coryell, P. R., Diekman, B. O., & Loeser, R. F. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00533-7 · Cited by 761

Muscles and their myokines

Pedersen, B. K. (2011) · Journal of Experimental Biology · doi:10.1242/jeb.048074 · Cited by 668

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672

Interleukin-6: designing specific therapeutics for a complex cytokine

Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643

Tocilizumab: A review in rheumatoid arthritis

Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0829-7 · Cited by 419

Exercise-Induced Changes in Visceral Adipose Tissue Mass Are Regulated by IL-6 Signaling: A Randomized Controlled Trial

Wedell-Neergaard, A.-S., Lang Lehrskov, L., Christensen, R. H., Legaard, G. E., Dorph, E., Larsen, M. K., Launbo, N., Fagerlind, S. R., Seide, S. K., Nymand, S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.007 · Cited by 403

Interleukin 6 as an Energy Allocator in Muscle Tissue

Kistner, T. M., Pedersen, B. K., & Lieberman, D. E. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00538-4 · Cited by 295

Role of interleukin-6 in stress, sleep, and fatigue

Rohleder, N., Aringer, M., & Boentert, M. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06634.x · Cited by 289

Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo

Axmann, R., Böhm, C., Krönke, G., Zwerina, J., Smolen, J., & Schett, G. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24781 · Cited by 263

Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance

Kraakman, M. J., Kammoun, H. L., Allen, T. L., Deswaerte, V., Henstridge, D. C., Estevez, E., Matthews, V. B., Neill, B., White, D. A., Murphy, A. J., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.006 · Cited by 257

IL-6 stimulates intestinal epithelial proliferation and repair after injury

Kuhn, K. A., Manieri, N. A., Liu, T.-C., & Stappenbeck, T. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114195 · Cited by 254

Biologics for targeting inflammatory cytokines, clinical uses, and limitations

Rider, P., Carmi, Y., & Cohen, I. (2016) · International Journal of Cell Biology · doi:10.1155/2016/9259646 · Cited by 226

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

Genovese, M. C., Fleischmann, R., Kivitz, A. J., Rell‐Bakalarska, M., Martincova, R., Fiore, S., Rohane, P., van Hoogstraten, H., Garg, A., Fan, C., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39093 · Cited by 219

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

Burmester, G. R., Rigby, W. F., van Vollenhoven, R. F., Kay, J., Rubbert-Roth, A., Kelman, A., Dimonaco, S., & Mitchell, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207628 · Cited by 194

The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations

Geiger, J. L., Grandis, J. R., & Bauman, J. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.022 · Cited by 193

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

Sieper, J., Porter-Brown, B., Thompson, L., Harari, O., & Dougados, M. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203559 · Cited by 184

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Pawar, A., Desai, R. J., Solomon, D. H., Santiago Ortiz, A. J., Gale, S., Bao, M., Sarsour, K., Schneeweiss, S., & Kim, S. C. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214367 · Cited by 181

Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

Song, S.-N. J., Iwahashi, M., Tomosugi, N., Uno, K., Yamana, J., Yamana, S., Isobe, T., Ito, H., Kawabata, H., & Yoshizaki, K. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4323 · Cited by 143

Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control

Lang Lehrskov, L., Lyngbaek, M. P., Soederlund, L., Legaard, G. E., Ehses, J. A., Heywood, S. E., Wewer Albrechtsen, N. J., Holst, J. J., Karstoft, K., Pedersen, B. K., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.008 · Cited by 135

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis

Ogata, A., Tanimura, K., Sugimoto, T., Inoue, H., Urata, Y., Matsubara, T., Kondo, M., Ueki, Y., Iwahashi, M., Tohma, S., et al. (2014) · Arthritis Care & Research · doi:10.1002/acr.22110 · Cited by 140

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

Smolen, J. S., Weinblatt, M. E., Sheng, S., Zhuang, Y., & Hsu, B. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205137 · Cited by 139

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

Sieper, J., Braun, J., Kay, J., Badalamenti, S., Radin, A. R., Jiao, L., Fiore, S., Momtahen, T., Yancopoulos, G. D., Stahl, N., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204963 · Cited by 127

Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis

Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L. (2017) · Nature Communications · doi:10.1038/ncomms15433 · Cited by 123

The role of interleukin-6 in glucose homeostasis and lipid metabolism

Lehrskov, L. L., & Christensen, R. H. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00747-2 · Cited by 114

Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.

Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S., & Bernasconi, C. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4397 · Cited by 105

Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan

Yamamoto, K., Goto, H., Hirao, K., Nakajima, A., Origasa, H., Tanaka, K., Tomobe, M., & Totsuka, K. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141210 · Cited by 91

Rheumatoid anemia

Masson, C. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.05.017 · Cited by 82

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production

Hashizume, M., Uchiyama, Y., Horai, N., Tomosugi, N., & Mihara, M. (2010) · Rheumatology International · doi:10.1007/s00296-009-1075-4 · Cited by 70

Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis

Ogata, A., Hirano, T., Hishitani, Y., & Tanaka, T. (2012) · Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders · doi:10.4137/cmamd.s7371 · Cited by 61

Tocilizumab

Scheinecker, C., Smolen, J., Yasothan, U., Stoll, J., & Kirkpatrick, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2863 · Cited by 49

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients

Takeuchi, T., Yamanaka, H., Harigai, M., Tamamura, R., Kato, Y., Ukyo, Y., Nakano, T., Hsu, B., & Tanaka, Y. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1536-9 · Cited by 18

Is liver cirrhosis a risk factor for osteonecrosis of the femoral head in adults? A population-based 3-year follow-up study

Hung, T.-H., Hsieh, Y.-H., Tsai, C.-C., Tseng, C.-W., Tseng, K.-C., & Tsai, C.-C. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.5952 · Cited by 11